Breast Cancer | Specialty

FDA Accepts Sacituzumab Govitecan Application for TNBC

December 27th 2019

The FDA has accepted a biologics license application for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer who have received at least 2 prior therapies for metastatic disease.

Current Advancements in HER2+ Breast Cancer Management

December 24th 2019

HER2CLIMB-02 Trial Regimen Toxicities and Impact

December 24th 2019

The HER2CLIMB-02 Trial Design, Results and Implications

December 24th 2019

HER2+ Breast Cancer: Brain Metastasis Prevalence & Later-Line Therapy

December 24th 2019

Emerging Data for the Treatment of HER2+ mBC

December 24th 2019

HER2+ mBC: Systemic Therapies and HER2CLIMB-02 Trial

December 24th 2019

Management of CNS Metastases in R/R HER2+ mBC

December 24th 2019

HER2+ Metastatic Breast Cancer: Standard of Care Therapies

December 24th 2019

Dr. Traina on the FDA Approval of Trastuzumab Deruxtecan for HER2+ Breast Cancer

December 21st 2019

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) for patients with HER2-positive, locally advanced, or metastatic breast cancer who have been treated with trastuzumab (Herceptin) and pertuzumab (Perjeta) and have disease progression after ado-trastuzumab emtansine (T-DM1; Kadcyla).

Talking Tumors: Weill Cornell Medicine Experts Walk Through Challenging Breast Cancer Cases

December 18th 2019

Lisa Newman, MD, MPH, FACS, FASCO, and Alan B. Astrow, MD, discuss the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor-positive, HER2-negative breast cancer.

Analysis Unable to Achieve Concordance Among PD-L1 Assays in TNBC

December 16th 2019

Mathematical modeling was unable to harmonize the VENTANA SP263 and Dako 22C3 PD-L1 assays with the FDA-approved VENTANA PD-L1 SP142 companion diagnostic for the selection of patients with advanced triple-negative breast cancer appropriate for atezolizumab plus nab-paclitaxel.

Adjuvant Chemo Shows Slight Benefit in Younger Women With Breast Cancer Who Have Mixed Clinical, Genomic Risk

December 16th 2019

Patients with premenopausal breast cancer and discordant clinical and genomic risk had a small increase in distant metastasis if they did not receive adjuvant chemotherapy, according to a post hoc analysis of the MINDACT trial.

Dr. Rugo on Updated Data From the SOPHIA Trial in HER2+ Metastatic Breast Cancer

December 14th 2019

Hope S. Rugo, MD, discusses the updated data from the phase III SOPHIA trial for patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies, presented at the 2019 San Antonio Breast Cancer Symposium.

Neoadjuvant Olaparib Combo Safe in Breast Cancer

December 14th 2019

Adding the PARP inhibitor olaparib to neoadjuvant platinum based-chemotherapy was determined to be a safe treatment for patients with triple-negative breast cancer, as well as for patients with breast cancer whose tumors harbor germline BRCA mutations.

Chemo-Free Regimen Matches Neoadjuvant Chemo in HR+/HER2- Breast Cancer

December 14th 2019

Almost half of patients with high-risk luminal-B breast cancer converted to a low risk of recurrence following chemotherapy-free neoadjuvant therapy, matching the performance of standard chemotherapy in small randomized trial.

ctDNA and CTCs Potentially Poised to Predict Recurrence for Early TNBC

December 14th 2019

The presence of circulating tumor DNA and circulating tumor cells following neoadjuvant chemotherapy can be an independent predictor of disease recurrence in patients with early triple-negative breast cancer.

Residual Cancer Burden Predicts Patient Outcomes Across Breast Cancer Subtypes

December 14th 2019

Residual cancer burden after neoadjuvant chemotherapy has been shown to be an accurate long-term predictor of disease recurrence and survival across all breast cancer subtypes.

Oral Regimen for Paclitaxel Administration May Become Available in Breast Cancer

December 13th 2019

The addition of encequidar (HM30181A) to oral paclitaxel is the first oral taxane regimen to result in an improvement in overall response rates as compared with an intravenous administration of paclitaxel in patients with metastatic breast cancer.

Estrogen Decreases Breast Cancer Incidence in Postmenopausal Women, Estrogen Plus Progestin Has Opposite Effect

December 13th 2019

Estrogen alone as menopausal hormone therapy was found to decrease breast cancer incidence in postmenopausal women.